



FAX RECEIVED

APR 16 1999

GROUP 1600

Legal Division

Pfizer Inc.

235 East 42nd Street

New York, NY 10017

OFFICIAL

Facsimile Transmission

NOTICE OF CONFIDENTIALITY

This transmission is intended only for the use of the Addressee and may contain information that is: 1. Subject to attorney/client privilege; 2. Attorney work product; or 3. Confidential. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of the information contained in this facsimile is strictly unauthorized and prohibited. If you have received this facsimile in error, please notify us immediately by collect telephone call to the sender named below. Thank you.

To:

U.S. Patent Office

Location:

Crystal City, VA

Facsimile Telephone:

703-308-4556

No. of Pages: (including this page)

3

From:

E. VICTOR DONAHUE

Department Name: Legal Division

Charge No.: 88421

Facsimile Telephone: (212) 883-5235

Date:

4/15/99

Time (New York)

5:38 PM

TO CONFIRM RECEIPT OF TRANSMISSION, CALL 212 573-2896

attn: Examiner C. Delacroix-Muirheid

E. V. L. Douth

Pfizer, Inc.
Patent Department, 20th floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-2739

04/15/99 THU 17:42 [TX/RX NO 7242] 002

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted this day to the Assistant Commissioner for Patents, Washington DC 20231, at 703-308-4556 on April 15, 1999 for the attention of Examiner C. Delacroix-Muirheid.

By

OFFICIAL

E. V. Donahue

E. Victor Donahue

FAX RECEIVED

APR 16 1999

GROUP 1600

#5
B.J.
4/16/99

BY TELEFACSIMILE FROM: (212) 883-5325

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: John A. Lowe

Examiner: C. Delacroix-Muirheid

APPLICATION NO.: 09/007,268

Group Art Unit: 1654

FILING DATE: January 14, 1998

TITLE: Fluoroalkoxybenzylamino Derivatives
of Nitrogen Containing HeterocyclesAssistant Commissioner for Patents
Washington, D.C. 20231Response to Requirement of Restriction and Election of Species

The present paper is in response to the Official Action of March 18, 1999 whereinby the Examiner has requested both restriction of the claims to one of inventions I through V, as classified in the Official Action, and also election of species pursuant to 37 CFR 1.146.

In response and without traverse, Applicant elects the claims of Group V, that is, Nos. 27, 29, and 31 drawn to method of use.

Since Group V (method of use) has been elected, the Examiner has also requested that for search purposes, a single method of use (clinical indication) be designated. In response to the Examiner's request, Applicant designates inflammatory bowel disease.

With respect to Applicant's election under 37 CFR 1.146, it is believed that a more generic claim is allowable, and upon indication of allowability as to the species, Applicant respectfully requests consideration of claim(s) directed to other clinical conditions.

The Examiner is invited to contact the undersigned if any further information is needed. No fee is believed due at this time since response is being made within the 30 day shortened period set by the Office. In the unlikely event that a fee is due, the Patent Office is authorized to charge the Pfizer Deposit Account, No. 16-1445.

131866